Factors significant for overall and progression-free survival in multivariate analysis
| Outcome . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Overall survival: disease status at HSCT,AP/BP vs CP1/CP2 | 2.26 | (1.18-4.34) | .014 |
| Progression-free survival | |||
| Disease status at SCT, AP/BP vs CP1/CP2 | 1.85 | (1.04-3.31) | .04 |
| Allotype | |||
| 1 Ag mismatch related | 5.69 | (1.73-18.71) | .004 |
| Matched unrelated | Referent | — | — |
| Matched related | 0.30 | (0.14-0.63) | .079 |
| Acute GVHD: Yes/no | 0.47 | (0.26-0.85) | .01 |
| Outcome . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| Overall survival: disease status at HSCT,AP/BP vs CP1/CP2 | 2.26 | (1.18-4.34) | .014 |
| Progression-free survival | |||
| Disease status at SCT, AP/BP vs CP1/CP2 | 1.85 | (1.04-3.31) | .04 |
| Allotype | |||
| 1 Ag mismatch related | 5.69 | (1.73-18.71) | .004 |
| Matched unrelated | Referent | — | — |
| Matched related | 0.30 | (0.14-0.63) | .079 |
| Acute GVHD: Yes/no | 0.47 | (0.26-0.85) | .01 |
— indicates not applicable; CI, confidence interval; CP1, chronic phase 1; CP2, chronic phase 2; and BP, blast phase.